Bain Capital Life Sciences — 2026 Investments
5 investments dated 2026 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)Alex Martin(Chief Executive Officer)
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham VenturesREDMILE+8 more
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.
BiotechHealthtechMedical DevicesCambridge, US
Andrew Adamovich(Director)Philina Lee(Executive Officer, Director)Aaron Pickett(Executive Officer)
BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)
Co-investorsCatalio Capital Management, LPProto AxiomSV Health InvestorsTenmileAbingworthAlly Bridge Group+2 more
Beeline provides a Vendor Management System (VMS) and extended workforce platform that helps enterprises manage their non-employee and external labor, covering compliance, cost control, and risk.
Enterprise SoftwareFuture of WorkHR TechSaaS
Co-investorsAcadian Ventures Management, Llc
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardMichelle Doig(Director)inAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)
Co-investorsAtlas VentureJanus Henderson InvestorsLAVOmega FundsvenBio Global StrategicvenBio Partners+1 more
Chronus (at imperative.com) offers an AI-assisted mentoring and connection platform that matches employees for guided conversations covering career development, mentorship, community building, and change adoption.
Future of WorkHR TechSaaSNew York, US
Co-investorsVoyager CapitalAlly Bridge GroupCatalio Capital Management
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.